Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Ajani
Jaffer A. Ajani, Houston, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20100216131 | GENE EXPRESSION PROFILING OF ESOPHAGEAL CARCINOMAS - The present invention generally regards gene expression profiling of esophageal cancers, including localized esophageal cancers. In particular, gene expression for a particular group of genes identifies individuals that are either going to be responsive to cancer therapy, for example chemotherapy and/or radiation, or that are not going to be responsive to cancer therapy. Exemplary genes having such expression profiles include, for example, PERP, S100A2, and SPRR3. | 08-26-2010 |
Mauro Ajani, Lainate IT
| Patent application number | Description | Published |
|---|---|---|
| 20110092472 | ENZYMATIC PROCESS FOR OBTAINING 17 ALPHA- MONOESTERS OF CORTEXOLONE AND/OR ITS 9,11- DEHYDRODERIVATIVES - The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. | 04-21-2011 |
Mauro Ajani, Lainate (milano) IT
| Patent application number | Description | Published |
|---|---|---|
| 20090023696 | USE OF C3-C10 17ALFA-ESTERS OF 9,11-DEHYDROCORTEXOLONE AS ANTI-GONADOTROPHIC AGENTS - The present invention relates to the use of C | 01-22-2009 |
| 20090264396 | 17Alpha, 21-Dihydroxypregnene esters as antiandrogenic agents - 17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof. | 10-22-2009 |
| 20100004157 | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL OR RECTAL ADMINISTRATION OF PROTEIN SUBSTANCES - Pharmaceutical compositions with differentiated, controlled and/or site-specific release are claimed for the oral or rectal administration of peptide or protein substances, including antibodies and soluble receptors capable of antagonising the pathogenetic role of several cell mediators such as interleukines, chemokines, growth factors, tissue necrosis factors, and interferons. Through the incorporation of the peptide or protein substance inside a controlled and/or site-specific release preparation, the application of this invention permits transporting the substances directly into the intestinal environment where a reduced quantity of proteolytic enzymes is present, a less aggressive microenvironment for the integrity of the protein structure and sequence. | 01-07-2010 |
Mauro Ajani, Milano IT
| Patent application number | Description | Published |
|---|---|---|
| 20090011010 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 01-08-2009 |